| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/13/2009 | US20090202523 Antibodies against a peptide epitope of apoliporotein b |
| 08/13/2009 | US20090202522 Use of goat serum for veterinary treatment |
| 08/13/2009 | US20090202521 Bifunctional Polyazamacrocyclic Chelating Agents |
| 08/13/2009 | US20090202520 Treatment and diagnostic methods for fibrosis related disorders |
| 08/13/2009 | US20090202517 Agents for improving inflammatory bowel disease |
| 08/13/2009 | US20090202516 Inhibition and treatment of gastrointestinal biofilms |
| 08/13/2009 | US20090202515 Agents for suppressing neural fibrotic degeneration |
| 08/13/2009 | US20090202514 Agents for improving chronic obstructive pulmonary diseases |
| 08/13/2009 | US20090202513 Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer |
| 08/13/2009 | US20090202512 Proteins for use in human and animal staphylococcus infections |
| 08/13/2009 | US20090202511 Targeted protein replacement for the treatment of lysosomal storage disorders |
| 08/13/2009 | US20090202510 Altered sumoylation of lamin a protein associated with dilated cardiomyopathy |
| 08/13/2009 | US20090202509 Methods and agents for reducing oxidative stress |
| 08/13/2009 | US20090202508 Negative regulation of hypoxia inducible factor 1 by os-9 |
| 08/13/2009 | US20090202507 Intelligent Nanomedicine Integrating Diagnosis And Therapy |
| 08/13/2009 | US20090202504 Methods for the detection and prognosis of breast tumors |
| 08/13/2009 | US20090202503 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
| 08/13/2009 | US20090202499 Human Telomerase Reverse Transcriptase Peptides |
| 08/13/2009 | US20090202497 Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| 08/13/2009 | US20090202494 Combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
| 08/13/2009 | US20090202491 Method for modulating, regulating and/or stabilizing angiogenesis |
| 08/13/2009 | US20090202488 Use Of The Foamy Virus Bet Protein For Inactivating APOBEC |
| 08/13/2009 | US20090202487 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
| 08/13/2009 | US20090202486 Difluorinated tripeptides as hcv serine protease inhibitors |
| 08/13/2009 | US20090202485 Heteroaryl-containing tripeptide hcv serine protease inhibitors |
| 08/13/2009 | US20090202484 Modulators of toll-like receptor 7 |
| 08/13/2009 | US20090202483 Hepatitis C Virus Inhibitors |
| 08/13/2009 | US20090202482 Prevention and Treatment of HCV Infection Employing Antibodies Directed Against Conformational and Linear Epitopes |
| 08/13/2009 | US20090202481 Composition for Sustained Release Delivery of Proteins or Peptides |
| 08/13/2009 | US20090202480 Macrocyclic serine protease inhibitors |
| 08/13/2009 | US20090202479 Method for modulating immune responses using stem cells and cytokines |
| 08/13/2009 | US20090202478 inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials |
| 08/13/2009 | US20090202477 Methods of treating infections using il-21 |
| 08/13/2009 | US20090202476 Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide |
| 08/13/2009 | US20090202475 Compositions and methods for treatment of microbial disorders |
| 08/13/2009 | US20090202474 Expression of orphan gpr64 in inflammatory diseases |
| 08/13/2009 | US20090202473 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart |
| 08/13/2009 | US20090202472 Molecules and chimeric molecules thereof |
| 08/13/2009 | US20090202471 Molecules with effects on cellular development and function |
| 08/13/2009 | US20090202470 Phosphonate Analogs of Hiv Inhibitor Compounds |
| 08/13/2009 | US20090202469 Detection of inflammatory disease and composition for preventing or treatment of inflammatory disease |
| 08/13/2009 | US20090202449 Use of osteopontin in dental formulations |
| 08/13/2009 | US20090202441 Compositions and methods to prevent cancer with cupredoxins |
| 08/13/2009 | US20090202440 Model animal of dendritic cell immunoreceptor gene knockout disease |
| 08/13/2009 | US20090202439 Methods for treatment of angiogenesis |
| 08/13/2009 | US20090202438 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | US20090202437 Therapeutic Use of Lpi, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory diseases |
| 08/13/2009 | US20090202433 Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses |
| 08/13/2009 | US20090202431 Stem-like cells in bone sarcomas |
| 08/13/2009 | US20090202430 Composition for cytocompatible, injectable, self-gelling polysaccharide solutions for encapsulating and delivering live cells or biologically active factors |
| 08/13/2009 | DE102008006716A1 Lipasenformulierung Lipasenformulierung |
| 08/13/2009 | CA2715266A1 Inhibition and treatment of gastrointestinal biofilms |
| 08/13/2009 | CA2715254A1 Compositions and methods for distraction osteogenesis |
| 08/13/2009 | CA2715127A1 Siva3, its preparation and use |
| 08/13/2009 | CA2714972A1 Use of p27kip1 for the prevention and treatment of heart failure |
| 08/13/2009 | CA2714514A1 Non-polymeric compositions for controlled drug delivery |
| 08/13/2009 | CA2714512A1 Compositions and methods which modulate g-protein signaling for the treatment of asthma |
| 08/13/2009 | CA2714506A1 Composition for sustained release delivery of proteins or peptides |
| 08/13/2009 | CA2714480A1 3,8-diaminotetrahydroquinoline derivative |
| 08/13/2009 | CA2714378A1 Treatment of chronic pain with zinc finger proteins |
| 08/13/2009 | CA2714251A1 Therapeutic peptidomimetic macrocycles |
| 08/13/2009 | CA2714200A1 Method for improving storage stability of glutathione |
| 08/13/2009 | CA2714082A1 Peptides and peptide mimetics to treat pathologies associated with eye disease |
| 08/13/2009 | CA2714007A1 Treatment of disease conditions via administration of dna repair enzyme |
| 08/13/2009 | CA2713416A1 Non-immunosuppressive cyclosporin for the treatment of a muscular dystrophy |
| 08/13/2009 | CA2713386A1 Liquid formulation of fsh |
| 08/13/2009 | CA2713348A1 Ester-based peptide prodrugs |
| 08/13/2009 | CA2713150A1 Methods for preventing or treating insulin resistance |
| 08/13/2009 | CA2713108A1 Inhibitors of cathepsin b |
| 08/13/2009 | CA2713032A1 Treatment of diseases and conditions mediated by eicosanoids |
| 08/13/2009 | CA2712824A1 Siva 2 stabilization |
| 08/13/2009 | CA2712606A1 Modified leptin polypeptides and their uses |
| 08/13/2009 | CA2712593A1 Methods for treating a condition characterized by dysfunction in protein homeostasis |
| 08/13/2009 | CA2700182A1 Cyclosporin compositions |
| 08/12/2009 | EP2088197A2 Haemophilus influenzae antigens and corresponding DNA fragments |
| 08/12/2009 | EP2088193A1 Novel shuttle vector |
| 08/12/2009 | EP2088188A1 Direct expression of peptides into culture media |
| 08/12/2009 | EP2088158A2 Monoclonal antibody against the CCR5 chemokine receptor |
| 08/12/2009 | EP2088157A1 Collagen peptide composition and food or beverage containing the same |
| 08/12/2009 | EP2088154A1 Methods and compositions for the treatment of gastrointestinal disorders |
| 08/12/2009 | EP2088153A1 Crystal of glutathione and process for production thereof |
| 08/12/2009 | EP2088152A1 N'-{n-[3-oxo-lupen-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropeonic acid and the pharmaceutically acceptable derivatives thereof, a method for the production and the use thereof in the form of a medicinal agent |
| 08/12/2009 | EP2087910A2 Polymeric prodrugs |
| 08/12/2009 | EP2087908A1 Antibodies to opgl |
| 08/12/2009 | EP2087906A1 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines |
| 08/12/2009 | EP2087905A2 Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
| 08/12/2009 | EP2087904A1 Therapeutic use of peptides derived from Bcl-XL protein in cancer patients |
| 08/12/2009 | EP2087885A1 Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases |
| 08/12/2009 | EP2087882A1 Drug microparticles |
| 08/12/2009 | EP2086998A1 Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| 08/12/2009 | EP2086994A2 Inhibitors of hepatitis c virus |
| 08/12/2009 | EP2086982A1 Hcv ns3 protease inhibitors |
| 08/12/2009 | EP2086642A2 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| 08/12/2009 | EP2086571A2 Tissue plasminogen activator variant uses |
| 08/12/2009 | EP2086570A1 Use of beta-lactamase |
| 08/12/2009 | EP2086569A2 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
| 08/12/2009 | EP2086568A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 08/12/2009 | EP2086567A1 Sustained release formulations comprising very low molecular weight polymers |
| 08/12/2009 | EP2086566A2 Compositions and methods for treating and diagnosing cancers |
| 08/12/2009 | EP2086565A2 Cosmetic and/or pharmaceutical composition containing at least one peptide as the active ingredient and use of said peptide |